Atezolizumab in Idiopathic Pulmonary Fibrosis

Summary

The purpose of this study is to evaluate the safety of atezolizumab, a medication currently used to treat various cancers, in individuals who have mild or moderate idiopathic pulmonary fibrosis (IPF). The study also aims to determine whether the medication can stop the progression of IPF. In addition, researchers will examine whether a biomarker test is helpful in deciding which patients are most likely to benefit from the study drug. A biomarker is a biological molecule found in blood, other body fluids or tissue and may be a sign of a condition or disease; it can be used to predict an individual's response to a specific treatment. The use of atezolizumab in this study is investigational.


Inclusion Criteria

  • Males or females ≥50 years of age
  • Confident diagnosis of IPF per 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline on Diagnosis of IPF1
Show more

Study Location(s)

Beverly : Millie Gomez

More about this Clinical Trial

Full Title

A Phase I Study to Evaluate the Safety and Preliminary Efficacy of Atezolizumab in Idiopathic Pulmonary Fibrosis

Details
Disease Type/Condition

Other

Principal Investigator

Zaman, Tanzira

Co-Investigators

Alain Mita, Paul Noble

Age Group

Adult

Phase

I

IRB Number

STUDY00001474

ClinicalTrials.gov ID

NCT05515627

Key Eligibility
ClinicalTrials.gov

Contact
Name

Millie Gomez

Phone
310-423-6252
Email
Millie.Gomez@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Other

Principal Investigator

Zaman, Tanzira

Age Group

Adult

Phase

I

IRB Number

STUDY1474

ClinicalTrials.gov ID

NCT05515627

Key Eligibility
ClinicalTrials.gov

Contact
Name

Millie Gomez

Phone
310-423-6252
Email
Millie.Gomez@cshs.org
Want to join the study or
learn more?